Raluca Ileana Mincu

Dr. Raluca Ileana Mincu

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen 45147, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRaluca Ileana Mincu
Raluca Ileana Mincu
LLLena F. Lampe
Lena F. Lampe
AMAmir Abbas Mahabadi
Amir Abbas Mahabadi
RKRainer Kimmig
Rainer Kimmig
Tienush RassafTienush Rassaf
Tienush Rassaf
MTMatthias Totzeck
Matthias Totzeck
Background: Anthracycline-based chemotherapy (ANT) remains among the most effective therapies for breast cancer. Cardiotoxicity from ANT represents a severe adverse event and may predominantly manifest as heart failure. While it is well-recognised that left ventricular systolic heart failure assessment is key in ANT-treated patients, less is known about the relevance of LV diastolic functional impairment and its characterisation. Methods: Studies reporting on echocardiographic diastolic function parameters before and after ANT in breast cancer patients without cardiac disease were included. We evaluated pulsed wave (E/A ratio and mitral E-wave deceleration time (EDT)) and tissue Doppler (mean velocities of the mitral ring in the early diastole (e′) and E/e′ ratio) echocardiographic parameters. Results: A total of 892 patients from 13 studies were included. E/A ratio was significantly reduced at the end of ANT while EDT was not influenced by ANT. Additionally, e’ and E/e’ ratio showed no significant change after ANT. A modest reduction in LV ejection fraction and global longitudinal strain was observed at the end of ANT therapy. Conclusions: ANT had a modest early impact on E/A ratio, without changing EDT, e’, or E/e’ in patients with breast cancer without cardiac disease. Randomised studies on larger populations, using new parameters are required to define the role of diastolic dysfunction in the early diagnosis of ANT-induced cardiotoxicity.

12 June 2024 in Life
Verified
Journal Article
Open access
PDF file
OEOuahiba El-Malahi
Ouahiba El-Malahi
DMDarya Mohajeri
Darya Mohajeri
Alexander BäuerleAlexander Bäuerle
Alexander Bäuerle
RMRaluca Ileana Mincu
Raluca Ileana Mincu
KRKorbinian Rothenaicher
Korbinian Rothenaicher
JLJulia Lortz
Julia Lortz
Stress is recognized as a significant trigger and exacerbator of various medical conditions, particularly in the field of cardiovascular disease (CVD). Given that heart rate variability (HRV) offers insight into the functioning of the autonomic nervous system and has been identified as a predictive factor for increased cardiovascular mortality, exploring the correlation between stress and HRV is pertinent. We systematically reviewed trials where researchers investigated the effects of stress-reducing interventions on biomarkers and time-domain/frequency-domain parameters of HRV in CVD. Eligible studies underwent meta-analysis utilizing a random-effects model. The meta-analysis showed overall beneficial effects of stress-reducing interventions on HRV for the standard deviation of Normal-to-Normal intervals (SDNN) in short-term and 24 h assessments, as well as for the low-frequency power (LF) in short-term assessment. Overall effect sizes were notably high and showed significant p-values (short-term SDNN: MD = 6.43, p = 0.01; 24 h SDNN: MD = 10.92, p = 0.004; short-term LF: MD = 160.11, p < 0.001). Our findings highlight the significant impact of stress-reducing interventions in modulating HRV by influencing short-term SDNN and LF parameters, as well as the 24 h assessment of SDNN. These results emphasize the importance of stress-reducing measures in lowering the risk of further progression in CVD and improving patient outcomes.

2 June 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
OEOuahiba El-Malahi
Ouahiba El-Malahi
DMDarya Mohajeri
Darya Mohajeri
Alexander BäuerleAlexander Bäuerle
Alexander Bäuerle
RMRaluca Ileana Mincu
Raluca Ileana Mincu
Christos RammosChristos Rammos
Christos Rammos
JLJulia Lortz
Julia Lortz
Background: Chronic stress is a critical factor influencing both physical and mental health. It can weaken the immune system, affect cardiovascular health, and lower quality of life, often leading to psychological disorders like anxiety and depression. Objective: This study aims to evaluate the effectiveness of eHealth stress management interventions on psychological health parameters, specifically anxiety, depression, stress, and quality of life in patients with cardiovascular disease (CVD). Methods: A comprehensive search was conducted across several databases, including the Cochrane Library, APA PsycInfo, Web of Science, PubMed, Embase, and clinical trial registers. Randomized controlled trials assessing the impact of eHealth stress management interventions, namely internet-based cognitive behavioral therapy (CBT), telephone-delivered CBT, internet-based stress management training, or telephone-delivered stress management training, on the specified psychological outcomes in patients with CVD were included. The control group comprised no intervention, a waitlist, (enhanced) usual care, or a web-based intervention not focusing on stress management. To evaluate potential bias, the Risk-of-Bias 2 tool was applied. A random-effects meta-analysis was performed using standard mean difference (SMD) as the effect size, with a sensitivity analysis using mean difference (MD). Results: A total of 6 randomized controlled studies were considered in the meta-analysis. In 5 studies internet-based CBT interventions were examined, while one study used an eHealth intervention based on a CBT approach. The control groups received either usual care, were placed on a waitlist, or participated in a web-based discussion forum. After the intervention period, which ranged from 8 weeks to 6 months, a significant reduction in depressive symptoms (SMD=−0.46, MD=−2.33; P<.001), as assessed by the Patient Health Questionnaire-9, was observed in the intervention group compared with the control group. Mental health–related quality of life, assessed by the subscale of the 12-Item Short-Form Health Survey, showed significant improvement (SMD=0.38, MD=3.89; P<.001) in the intervention group in comparison to the control group following the intervention period. Conclusions: The meta-analysis demonstrates that eHealth stress management interventions substantially improve psychological health parameters in patients with CVD. Given the significant positive impact, health care providers should consider integrating eHealth stress management programs into standard care for patients with CVD. These programs can be a valuable tool in mitigating the psychological burdens associated with chronic cardiovascular conditions, ultimately improving overall patient outcomes and quality of life.

Verified
Journal Article
Open access
PDF file
JPJulia Pohl
Julia Pohl
RMRaluca Ileana Mincu
Raluca Ileana Mincu
SMSimone Maria Mrotzek
Simone Maria Mrotzek
LHLena Hinrichs
Lena Hinrichs
LMLars Michel
Lars Michel
MTMatthias Totzeck
Matthias Totzeck
We aimed to evaluate whether therapy with immune checkpoint inhibitors (ICI) leads to changes in electrocardiogram (ECG) parameters in melanoma patients. We retrospectively examined 41 patients (46% women, age 61 ± 12years) with advanced melanoma (stage III/IV) before and during ICI treatment from our “Essen Cardio-oncology Registry” (ECoR). ECGs were analyzed before and 4–12 weeks after therapy started (follow-up, 90 ± 51 days). Heart rate, PR time, QRS duration and duration of the corrected QT (QTc) interval were recorded. QT dispersion (QTd) was calculated. Heart rate, PR time, QRS and QTc did not differ when comparing values before and after therapy started. QTd was prolonged after therapy started (32 ± 16 ms vs. 47 ± 19 ms, n = 41, p < 0.0001). Subgroup analyses revealed prolonged QTd in patients that received a combination immunotherapy with ipilimumab and nivolumab (31 ± 14 ms vs. 50 ± 14 ms, n = 21, p < 0.0001), while QTd in patients with anti–programmed death 1 (PD-1) inhibitor monotherapy did not change after therapy started. QTd is prolonged in patients under ICI combination therapy, potentially signaling an increased susceptibility to ventricular arrhythmias.

10 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JPJulia Pohl
Julia Pohl
RMRaluca Ileana Mincu
Raluca Ileana Mincu
SMSimone M. Mrotzek
Simone M. Mrotzek
RWReza Wakili
Reza Wakili
AMAmir Abbas Mahabadi
Amir Abbas Mahabadi
MTMatthias Totzeck
Matthias Totzeck
Objective: To evaluate a new electrocardiographic (ECG) score reflecting domains of electrical and structural alterations in therapy-naïve cancer patients to assess their risk of cardiotoxicity. Methods: We performed a retrospective analysis of 134 therapy-naïve consecutive cancer patients in our two university hospitals concerning four ECG score parameters: Contiguous Q-waves, markers of left ventricular (LV) hypertrophy, QRS duration and JTc prolongation. Cardiotoxicity was assessed after a short-term follow-up (up to 12 months). Results: Of all the patients (n = 25), 19% reached 0 points, 50% (n = 67) reached 1 point, 25% (n = 33) reached 2 points, 5% (n = 7) reached 3 points and 0.7% reached 4 or 5 points (n = 1 respectively). The incidence of cardiotoxicity (n = 28 [21%]) increased with the ECG score, with 0 points at 0%, 1 point 7.5%, 2 points 55%, 3 points 71% and ≥3 points 50%. In the ROC (Receiver operating curves) analysis, the best cut-off for predicting cardiotoxicity was an ECG score of ≥2 points (sensitivity 82%, specificity 82%, AUC 0.84, 95% CI 0.77–0.92, p < 0.0001) which was then defined as a high-risk score. High-risk patients did not differ concerning their age, LV ejection fraction, classical cardiovascular risk factors or cardiac biomarkers compared to those with a low-risk ECG score. Conclusion: ECG scoring prior to the start of anti-cancer therapies may help to identify therapy-naïve cancer patients at a higher risk for the development of cardiotoxicity.

19 December 2024 in Medicina
Verified
Journal Article
Open access
PDF file
SMStefania Lucia Magda
Stefania Lucia Magda
AGAna Maria Gheorghiu
Ana Maria Gheorghiu
RMRaluca Ileana Mincu
Raluca Ileana Mincu
ACAndrea-Olivia Ciobanu
Andrea-Olivia Ciobanu
TCTudor Constantinescu Constantinescu
Tudor Constantinescu Constantinescu
DVDragoș Vinereanu
Dragoș Vinereanu
Background and objectives: Systemic sclerosis (SSc) causes myocardial and microvascular impairment, with subclinical dysfunction and eventually permanent cardio-vascular damage. The long-term influence of SSc therapies on subclinical cardiovascular dysfunction is insufficiently investigated. We aimed to assess 2D and 4D cardiac ultrasound parameters of heart function in patients with different forms of SSc versus controls and to determine the evolution of cardiac function and arterial stiffness parameters under therapy. Materials and methods: A total of 60 subjects with SSc were studied at baseline; 30 SSc patients were compared to 30 matched controls. A total of 52 SSc subjects were reassessed after 1 year and 30 after 2 years of treatment. Cardiac function was evaluated through 2D standard echocardiography, tissue Doppler, speckle tracking and 4D auto LV quantification echo. Arterial stiffness was determined via the cardio-ankle vascular index and ankle brachial index. Results: At baseline, the standard echo parameters were normal. The 4D and myocardial work parameters, although in normal limits, were significantly altered in the SSc group vs. controls (4D ejection fraction 54.5 ± 8.5% in SSc vs. 63.8 ± 3.1% in controls; 4D longitudinal strain −14.2 ± 2.4% in SSc vs. −22.0 ± 2.7% in controls; global constructive work 2124.2 ± 449.5 mmHg% in SSc vs. 3102.8 ± 337.5 mmHg% in controls, for all p ≤ 0.02). Both at 1 year and 2 years of treatment, all echo and arterial stiffness parameters were similar to baseline, with no correlation to treatment type. Conclusions: SSc determines subclinical systolic dysfunction. Non-invasive assessment methods do not detect a functional cardiovascular decline in patients on classical therapy. Complex cardiac follow-up should be implemented in cases at risk for complications.